Gastrointestinal Cancers: Managed Care Strategies to Improve Resource Utilization With Immune Checkpoint Inhibitors
This activity will explain the influence biomarker testing assays have on the overall cost of drug therapy for patients with gastrointestinal (GI) cancer who are receiving treatment with an immune checkpoint inhibitor.
An Update on Targeted Therapies for Hepatocellular Carcinoma (HCC)
This article will analyze current and novel targeted therapies with proven efficacy in the treatment of HCC.
The Expanding Treatment Landscape of Inflammatory Bowel Disease: The Role of the Specialty Pharmacist
The activity will explore specialty pharmacy operational and clinical practices that have the greatest potential to improve outcomes for patients with IBD.
The Evolution of Immune Checkpoint Inhibitors in the Treatment of GI Cancers and the Pharmacist's Growing Role
This activity will review biomarkers useful for predicting patient response to immune checkpoint inhibitors and techniques for adherence monitoring will also be addressed to assist pharmacists in developing strategies to optimize the care and management of patients with GI cancers.